ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CHF10067

A development code. Also written as “CHF10067 starting dose -- 1000mg (Cohort A)”, “CHF10067 intermediate dose -- 2000mg (Cohort B)” and “CHF10067 high dose -- 3000mg (Cohort C)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Chiesi Farmaceutici.

Furthest: phase 2, since Apr 1, 20262 company-led studies, 1 open or runningNext primary completion: Jun 27, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici21 open or runningphase 2since Apr 1, 2026Aug 17, 2022Jun 27, 2028phase 2 · NCT07516951

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2022First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT05513950 · 52 enrolled · North Macedonia, Ukraine, United Kingdom
  2. Apr 1, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07516951 · 240 planned · United States, North Macedonia, South Korea and more

Ahead

  1. Jun 27, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07516951

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07516951Idiopathic Pulmonary Fibrosis · United States, North Macedonia, South Korea and more2RecruitingJun 27, 2028240
NCT05513950Idiopathic Pulmonary Fibrosis · North Macedonia, Ukraine, United Kingdom1CompletedJun 17, 202452

How it is read

Names in the registry

  • “CHF10067”, 2 entries
  • “CHF10067 starting dose -- 1000mg (Cohort A)”, 1 entry
  • “CHF10067 intermediate dose -- 2000mg (Cohort B)”, 1 entry
  • “CHF10067 high dose -- 3000mg (Cohort C)”, 1 entry

Codes read as this program: CHF10067.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.